FCGR3A and lung carcinoma: We discovered that CD16a/b shedding can be inhibited by a CD16a/b-targeting mAb (F9H4), which as consequence promotes NK cell-mediated cytotoxicity and interferon-γ production against lung cancer in the context of co-administration with two types of EGFR antibodies (cetuximab and necitumumab).